Structural basis of transcription inhibition by fidaxomicin (lipiarmycin A3)
Fidaxomicin is an antibacterial drug in clinical use for treatment of Clostridium difficile diarrhea. The active ingredient of fidaxomicin, lipiarmycin A3 (Lpm), functions by inhibiting bacterial RNA polymerase (RNAP). Here we report a cryo-EM structure of Mycobacterium tuberculosis RNAP holoenzyme...
主要な著者: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Cell Press
2018
|